Genentech-Roche's Avastin wins FDA nod for cervical cancer

08/15/2014 | Medscape (free registration)

Genentech and Roche Holding obtained the FDA's approval to market Avastin, or bevacizumab, as a treatment for recurrent, persistent or late-stage cervical cancer. The drug is to be given with paclitaxel in combination with cisplatin or topotecan. Avastin is already cleared for the treatment of four types of cancer.

View Full Article in:

Medscape (free registration)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
European Sales Manager
SentreHEART, Inc.
Germany, Benelux, UK
REG AFFAIRS PROJ MGR - 1400000A7F
Abbott
San Jose, CA
SPECIALIST II SYSTEMS INTEGRATION - 140000033P
Abbott
Dallas, TX
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD